Old Web
English
Sign In
Acemap
>
authorDetail
>
P. Dolin
P. Dolin
Takeda Pharmaceutical Company
Physical therapy
Medicine
Diabetes mellitus
Vedolizumab
Ulcerative colitis
5
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
2020
Journal of Crohns & Colitis
Edward E. Louis
V. Muls
Patrick M. M. Bossuyt
A. Colard
A. Nakad
D. Baert
Fazia Mana
Philip Caenepeel
S. Vanden Branden
S Vermeire
F D'Heygere
B. Strubbe
A. Cremer
Jc Coche
V. Setakhr
F Baert
A. Vijverman
J.-L. Coenegrachts
F. Flamme
A Hantson
K Wijnen
E Piters
P. Dolin
Show All
Source
Cite
Save
Citations (0)
P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01).
2017
Journal of Crohns & Colitis
Douglas C. Wolf
James D. Lewis
Britta Siegmund
Gary R. Lichtenstein
Shaji Sebastian
Corey A. Siegel
Édouard Louis
T. Haas
K. Nedd
Sreedhar Subramanian
Humberto Aguilar
Laurence J. Egan
Christoph Gasche
Glen A. Doherty
Alan J. Lobo
D. Spearman
Amir C. Patel
R. Moparty
M. Brookes
Xavier Hébuterne
Bjørn Moum
P. Dolin
Show All
Source
Cite
Save
Citations (0)
P590 Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)
2017
Journal of Crohns & Colitis
Shaji Sebastian
James D. Lewis
Britta Siegmund
Douglas C. Wolf
Corey A. Siegel
Gary R. Lichtenstein
Edouard Louis
Xavier Hébuterne
P.M. Ginsburg
A. Ostrov
M.Q. Ricci
M. Bernsen
Ira Shafran
Stéphane Nancey
Gordon W. Moran
N Teich
Simon Lal
M. Kiszka-Kanowitz
S. Murugesan
Bjørn Moum
P. Dolin
Show All
Source
Cite
Save
Citations (0)
1